United Therapeutics Co. (NASDAQ:UTHR) Shares Purchased by Colonial River Investments LLC

Colonial River Investments LLC lifted its holdings in United Therapeutics Co. (NASDAQ:UTHR) by 12.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,367 shares of the biotechnology company’s stock after purchasing an additional 154 shares during the quarter. Colonial River Investments LLC’s holdings in United Therapeutics were worth $482,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in UTHR. Y Intercept Hong Kong Ltd purchased a new position in United Therapeutics in the 4th quarter worth $2,177,000. Fjarde AP Fonden Fourth Swedish National Pension Fund raised its stake in United Therapeutics by 8.9% in the 4th quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 23,300 shares of the biotechnology company’s stock worth $8,221,000 after acquiring an additional 1,900 shares during the last quarter. Access Investment Management LLC raised its stake in United Therapeutics by 0.8% in the 4th quarter. Access Investment Management LLC now owns 7,335 shares of the biotechnology company’s stock worth $2,588,000 after acquiring an additional 55 shares during the last quarter. Hussman Strategic Advisors Inc. raised its stake in United Therapeutics by 33.3% in the 4th quarter. Hussman Strategic Advisors Inc. now owns 8,400 shares of the biotechnology company’s stock worth $2,964,000 after acquiring an additional 2,100 shares during the last quarter. Finally, Ieq Capital LLC raised its stake in United Therapeutics by 307.6% in the 4th quarter. Ieq Capital LLC now owns 6,852 shares of the biotechnology company’s stock worth $2,418,000 after acquiring an additional 5,171 shares during the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Analyst Upgrades and Downgrades

UTHR has been the subject of a number of research analyst reports. The Goldman Sachs Group raised their target price on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. Oppenheimer lifted their price objective on United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price objective on United Therapeutics from $319.00 to $344.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. HC Wainwright lifted their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. Finally, Argus lifted their price target on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a research note on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $388.25.

Insider Buying and Selling

In other news, EVP Paul A. Mahon sold 7,700 shares of the business’s stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the transaction, the executive vice president now directly owns 36,710 shares in the company, valued at $13,743,122.70. The trade was a 17.34 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Louis W. Sullivan sold 26,209 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total value of $9,781,722.98. Following the transaction, the director now owns 5,051 shares in the company, valued at approximately $1,885,134.22. This represents a 83.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 114,164 shares of company stock worth $41,671,293. Insiders own 11.90% of the company’s stock.

United Therapeutics Trading Down 1.7 %

UTHR stock opened at $361.10 on Monday. United Therapeutics Co. has a 12-month low of $214.75 and a 12-month high of $417.82. The stock has a market cap of $16.12 billion, a price-to-earnings ratio of 15.86, a PEG ratio of 0.97 and a beta of 0.57. The business’s 50-day moving average is $362.68 and its 200 day moving average is $360.72.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.